Indian Drug Schedules
Drug Pricing in India: NPPA, DPCO 2013 and the National List of Essential Medicines
How drug prices are controlled in India -- the role of NPPA, the Drug Price Control Order 2013, ceiling prices, NLEM and trade margin rationalisation explained.
MedNext Academy | 6 min read
Drug Pricing in India: NPPA, DPCO 2013 and the National List of Essential Medicines
How drug prices are controlled in India -- the role of NPPA, the Drug Price Control Order 2013, ceiling prices, NLEM and trade margin rationalisation explained.
How Are Drug Prices Controlled in India?
India has one of the most extensive drug price control regimes in the world. The National Pharmaceutical Pricing Authority (NPPA), established in 1997 under the Department of Pharmaceuticals (Ministry of Chemicals and Fertilisers), is the regulatory body responsible for fixing and revising ceiling prices of scheduled drugs, enforcing price compliance, and monitoring drug prices across the country.
The legal framework for price control is the Drug (Prices Control) Order, 2013 (DPCO 2013), issued under Section 3 of the Essential Commodities Act, 1955. DPCO 2013 replaced the earlier DPCO 1995, introducing a market-based pricing methodology that represented a fundamental shift in India's approach to pharmaceutical price regulation.
The Drug (Prices Control) Order, 2013
DPCO 2013 introduced the concept of ceiling prices based on market data rather than cost-plus calculations. The key mechanism works as follows:
For drugs listed in the National List of Essential Medicines (NLEM), the ceiling price is calculated as the simple average of all brands with a market share of 1% or more of the total market turnover of that drug formulation. This is a significant departure from the cost-based pricing under DPCO 1995.
The formula for ceiling price is: Ceiling Price = Simple Average of Prices of All Brands Having Market Share >= 1%. The ceiling price is adjusted annually based on the Wholesale Price Index (WPI) for the relevant category.
For non-scheduled formulations (drugs not on the NLEM), DPCO 2013 contains a general provision under Paragraph 20 that empowers the NPPA to fix the price of any drug in "extraordinary circumstances in the public interest" even if it is not on the NLEM. This "extraordinary circumstances" power has been used by NPPA to cap prices of cardiac stents, knee implants, cancer drugs and other products.
The National List of Essential Medicines (NLEM)
The NLEM is the foundation of India's drug price control system. Only drugs listed on the NLEM are subject to automatic ceiling price controls under DPCO 2013. The NLEM is revised periodically by a committee constituted by the Ministry of Health and Family Welfare.
Key NLEM revisions include NLEM 2011 with 348 drugs, NLEM 2015 with 376 drugs, and NLEM 2022 with 384 drugs across 27 therapeutic categories. Drugs recently added to the NLEM include several anti-cancer drugs, anti-diabetics, cardiovascular drugs and anti-infective agents.
Examples of NLEM drugs with controlled ceiling prices: - Metformin 500 mg tablets -- ceiling price fixed by NPPA - Atorvastatin 10 mg tablets -- ceiling price fixed by NPPA - Amlodipine 5 mg tablets -- ceiling price fixed by NPPA - Paracetamol 500 mg tablets -- ceiling price fixed by NPPA - Ciprofloxacin 500 mg tablets -- ceiling price fixed by NPPA - Enalapril 5 mg tablets -- ceiling price fixed by NPPA - Metoprolol 50 mg tablets -- ceiling price fixed by NPPA - Ranitidine 150 mg tablets -- ceiling price fixed by NPPA - Amoxicillin 500 mg capsules -- ceiling price fixed by NPPA - Losartan 50 mg tablets -- ceiling price fixed by NPPA
How NPPA Fixes and Enforces Ceiling Prices
The NPPA's process for fixing ceiling prices involves collecting market data from pharmaceutical companies (through Form V submissions), calculating the simple average of prices of brands with 1% or more market share, publishing the ceiling price in the official gazette, and allowing a transition period for companies to comply.
Enforcement mechanisms include monitoring retail prices through the Pharma Jan Samadhan portal and the NPPA helpline (1800-111-255), issuing price reduction orders where non-compliance is found, demanding overcharged amounts from manufacturers, imposing penalties including interest on overcharged amounts at 15% per annum, and recovering excess amounts collected from consumers.
NPPA publishes monthly price lists and maintains a searchable database of ceiling prices on its website.
Trade Margin Rationalisation
In addition to ceiling prices, the government has implemented Trade Margin Rationalisation (TMR) for certain categories. Under TMR, the maximum retail price of a drug cannot exceed a specified percentage over the price to the first distributor. This approach has been applied to anti-cancer drugs (42 drugs) where MRP is capped at a maximum margin over the price to the stockist.
The TMR approach addresses a different problem from ceiling prices -- it targets the markup in the distribution chain rather than the manufacturer's price. Some cancer drugs were being sold at markups of 500-1000% over the manufacturer's price, and TMR was designed to eliminate this.
Penalties for Price Violations
Under DPCO 2013, selling a scheduled drug above its ceiling price is a violation punishable under the Essential Commodities Act, 1955. Penalties include recovery of the overcharged amount from the manufacturer, interest at 15% per annum on the overcharged amount from the date of overcharge, imprisonment of up to seven years for violations of essential commodities pricing, and potential cancellation of the drug manufacturing licence.
NPPA has actively enforced price compliance, issuing demand notices totalling thousands of crores of rupees against pharmaceutical companies. Several high-profile cases have involved multinational companies being asked to refund overcharged amounts.
Impact on the Pharmaceutical Industry
Drug price control has significant implications for the pharmaceutical industry. Arguments in favour include ensuring affordability of essential medicines for India's largely out-of-pocket healthcare system, preventing exploitative pricing especially for life-saving drugs, and promoting competition among generic manufacturers.
Arguments against include reduced incentives for research and development of new drugs for the Indian market, the potential withdrawal of low-margin products from the market (creating shortages), and the complexity of compliance with frequently changing ceiling prices.
The pharmaceutical industry, represented by bodies such as the Indian Pharmaceutical Alliance (IPA) and the Organisation of Pharmaceutical Producers of India (OPPI), has engaged in extensive dialogue with the government on these issues.
Relevance to NEET PG and Pharmacology Exams
Drug pricing and NPPA are tested in pharmacology papers, particularly in the section on drug legislation and ethics. Key exam points include the role of NPPA (the price regulator) versus CDSCO (the drug quality regulator), the mechanism of ceiling price calculation under DPCO 2013 (simple average of brands with >= 1% market share), the relationship between NLEM and DPCO (only NLEM drugs get automatic ceiling prices), the extraordinary circumstances power under Paragraph 20 of DPCO 2013, and the year of establishment of NPPA (1997) and DPCO 2013.
Questions often test the distinction between NPPA and CDSCO, the mechanism of ceiling price calculation, and the scope of price control (scheduled vs non-scheduled drugs).
Recent Updates and Changes
Recent developments include the revision of NLEM 2022 adding 34 new drugs and deleting 26, expanding price controls to additional formulations. NPPA has continued to use its Paragraph 20 powers for non-scheduled drugs, most notably for cancer drugs and medical devices. The government has also introduced price caps on medical devices including cardiac stents, knee implants and drug-eluting stents.
The pharmaceutical industry has challenged several NPPA orders in courts, and the legal framework continues to evolve through judicial interpretation. The government is also exploring the integration of price monitoring with the Ayushman Bharat health insurance scheme to ensure that beneficiaries are not charged above ceiling prices.
Regulatory governance
**Authority:** Central Drugs Standard Control Organisation (CDSCO), Government of India. **Legislation:** Drugs and Cosmetics Act, 1940 and Rules, 1945 (as amended). **Publication state:** Awaiting review. **Correction:** Report errors at support@mednext.academy.
Frequently Asked Questions
What is NPPA and what does it do?
The National Pharmaceutical Pricing Authority (NPPA) is the regulatory body that fixes and enforces ceiling prices of essential drugs in India. Established in 1997, it operates under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers. NPPA monitors drug prices, ensures compliance with DPCO 2013, and can cap prices of any drug under extraordinary circumstances.
How is the ceiling price of a drug calculated under DPCO 2013?
The ceiling price is calculated as the simple average of the prices of all brands of a particular drug formulation that have a market share of 1% or more. This market-based approach replaced the earlier cost-plus methodology under DPCO 1995. The ceiling price is adjusted annually based on the Wholesale Price Index.
Are all drugs in India price-controlled?
No. Only drugs listed on the National List of Essential Medicines (NLEM) are subject to automatic ceiling price control under DPCO 2013. However, NPPA has the power under Paragraph 20 of DPCO 2013 to fix prices of non-NLEM drugs in 'extraordinary circumstances in the public interest.' This power has been used for cancer drugs, cardiac stents and knee implants.
What is the difference between NPPA and CDSCO?
NPPA regulates drug PRICES -- it fixes ceiling prices and ensures affordability. CDSCO regulates drug QUALITY, SAFETY and EFFICACY -- it approves new drugs, inspects manufacturers, and classifies drugs into schedules (H, H1, X, etc.). They are separate bodies under different ministries. NPPA is under Chemicals and Fertilisers; CDSCO is under Health and Family Welfare.
What happens if a company sells a drug above the ceiling price?
The company must refund the overcharged amount and pay interest at 15% per annum from the date of the overcharge. Under the Essential Commodities Act, violations can attract imprisonment of up to seven years. NPPA has issued demand notices worth thousands of crores against pharmaceutical companies for ceiling price violations.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
FormularyDrug Formulary
Individual drug profiles with Indian brands, dosing and exam pearls.
Subject HubPharmacology Hub
All pharmacology resources in one place.
Test your drug schedule knowledge
Test your knowledge of Indian drug regulation with targeted MCQs on schedules, prescribing rules and the Drugs and Cosmetics Act.
Test drug schedule knowledge

